Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 3

Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)

Authors Enriqueta Felip, Rafael Rosell

Published 6 June 2008 Volume 2008:4(3) Pages 579—585

DOI https://doi.org/10.2147/TCRM.S2248

Enriqueta Felip1, Rafael Rosell2

1Vall d’Hebron University Hospital, Barcelona, Spain; 2Institut Català d’Oncologia, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain

Abstract: NSCLC accounts for 80% of all cases of lung cancer, which is the leading cause of cancer mortality. The majority of NSCLC patients present with advanced, unresectable disease, which remains incurable. In advanced disease, chemotherapy with platinum (cisplatin or carboplatin) in combination with a third-generation cytotoxic drug (vinorelbine, gemcitabine, paclitaxel, or docetaxel) can provide a modest improvement in survival without impairing quality of life. In chemotherapy-naïve, advanced, non-squamous NSCLC patients, the combination of bevacizumab with chemotherapy was shown to produce better outcomes than chemotherapy alone. Response rates of 20%–40% can now be expected, with a median survival of 8–11 months and a 1-year survival rate of 30%–40%. In second-line treatment, docetaxel has shown superiority to best supportive care in terms of survival and quality of life. A pooled analysis comparing docetaxel administered weekly versus 3-weekly found similar survival rates between the schedules and a non-significant reduction in febrile neutropenia for the weekly regimen. Pemetrexed, a multitargeted antifolate agent, has shown clear activity in several tumors, including mesothelioma and NSCLC. In a phase III trial, second-line treatment with pemetrexed demonstrated overall survival comparable to docetaxel, with a more manageable toxicity profile.

Keywords: pemetrexed, second-line therapy, NSCLC

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Can dynamic contour tonometry and ocular pulse amplitude help to detect severe cardiovascular pathologies?

Bertelmann T, Langanke S, Potstawa M, Strempel I

Clinical Ophthalmology 2014, 8:1317-1321

Published Date: 14 July 2014

Effects of titania nanotubes with or without bovine serum albumin loaded on human gingival fibroblasts

Liu X, Zhou X, Li S, Lai R, Zhou Z, Zhang Y, Zhou L

International Journal of Nanomedicine 2014, 9:1185-1198

Published Date: 6 March 2014

Flower-shaped ZnO nanoparticles synthesized by a novel approach at near-room temperatures with antibacterial and antifungal properties

Khan MF, Hameedullah M, Ansari AH, Ahmad E, Lohani MB, Khan RH, Alam MM, Khan W, Husain FM, Ahmad I

International Journal of Nanomedicine 2014, 9:853-864

Published Date: 10 February 2014

Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy

Foody JM, Toth PP, Tomassini JE, Sajjan S, Ramey DR, Neff D, Tershakovec AM, Hu H, Tunceli K

Vascular Health and Risk Management 2013, 9:719-727

Published Date: 15 November 2013

Paclitaxel-loaded poly(glycolide-co-ε-caprolactone)-b-D-α-tocopheryl polyethylene glycol 2000 succinate nanoparticles for lung cancer therapy

Zhao TJ, Chen HZ, Dong YC, Zhang JJ, Huang HD, Zhu J, Zhang W

International Journal of Nanomedicine 2013, 8:1947-1957

Published Date: 16 May 2013